Sensus Healthcare, Inc. SRTS
Regular-session close
After hours · Nov 19, 7:30 PM ET
- YTD
- -40.70%
- 1 year
- -41.58%
- Market cap
- 38.85M
- Revenue (ttm)
- 36.37M
- Profit margin
- 18.27%
- EPS (ttm)
- -0.97
- Shares out
- 16.39M
- Forward P/E
- 11.84
- YTD return
- -40.70%
- 1-year return
- -41.58%
- Volume
- 170.42K
- Avg volume
- 206.16K
- Open
- 2.30
- Previous close
- 2.30
- Day's range
- 2.30 – 2.51
- 52-week range
- 2.14 – 5.49
- Beta
- 1.04
- Price target
- 11.50 (+387.3%)
Key statistics
- 50-day average
- 7.53
- 200-day average
- 5.81
- Enterprise value
- 112.66M
- Price / sales
- 3.10
- Price / book
- 4.39
- Revenue growth
- 155.70%
- Free cash flow
- -2.92M
- Total cash
- 14.52M
- Total debt
- 225.00K
- Return on equity
- 13.44%
- Short % of float
- 3.61%
Fundamental scorecard
7 of 25 checks passed on SRTS’s reported financials
7of 25 checks passed
- Value 2 of 5
- Growth 2 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 13, 2025 | Dec 1, 2024 | 0.10 | — | — | — |
| Nov 14, 2024 | Sep 1, 2024 | -0.02 | 0.07 | +0.09 | +450.00% |
| Aug 8, 2024 | Jun 1, 2024 | 0.03 | 0.10 | +0.07 | +233.33% |
| May 9, 2024 | Mar 1, 2024 | -0.04 | 0.14 | +0.18 | +450.00% |
| Feb 8, 2024 | Dec 1, 2023 | 0.12 | 0.26 | +0.14 | +116.67% |
| Nov 9, 2023 | Sep 1, 2023 | -0.01 | -0.09 | -0.08 | -800.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 18, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 15, 2024 | Maxim Group | main | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 13, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| May 10, 2024 | Maxim Group | main | Buy | Buy |
| Nov 13, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Sensus Healthcare, Inc.
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- sensushealthcare.com
News
What Sensus Healthcare (SRTS) Said on Its Q3 Earnings Call
Sensus Healthcare, Inc. (SRTS) Q3 2026 Earnings Call Transcript Sensus Healthcare Q3 EPS $(0.09) Misses $(0.06) Estimate, Sales $5.995M Miss $6.614M Estimate
Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights
Your note
Sign in to keep a note on SRTS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CORNISH MEGAN | Director | Stock Award(Grant) | Dec 16, 2024 | 32,000 |
| HEINRICH JOHN P. PH.D. | Director | Sale | May 19, 2024 | 59,940 |
| MCCALL WILLIAM H | Director | Stock Award(Grant) | Dec 16, 2024 | 30,000 |
| O'REAR SAMUEL | Director | Purchase | May 8, 2023 | 143,570 |
| PETRELLI ANTHONY BENEDICT | Director | Stock Award(Grant) | Dec 16, 2024 | 66,466 |
| SARDANO JOSEPH C | Chief Executive Officer | Purchase | Sep 13, 2023 | 1,175,290 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 4.75% | 779,052 | 5.35M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 2.50% | 409,334 | 2.81M | Sep 29, 2024 |
| Acadian Asset Management. LLC | 1.85% | 303,915 | 2.09M | Sep 29, 2024 |
| Dimensional Fund Advisors LP | 1.77% | 289,615 | 1.99M | Sep 29, 2024 |
| Morgan Stanley | 1.13% | 185,268 | 1.27M | Sep 29, 2024 |
| Two Sigma Investments, LP | 0.94% | 154,044 | 1.06M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.39% | 555,562 | 3.82M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.27% | 207,423 | 1.42M | Sep 29, 2024 |
| Perritt Microcap Opportunities Fund | 0.58% | 95,000 | 652.65K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.46% | 76,080 | 522.67K | Oct 30, 2024 |
| Unified Series Trust-Auer Growth Fd | 0.31% | 50,000 | 343.50K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.21% | 34,229 | 235.15K | Oct 30, 2024 |
